Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takis S R L is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This application is being reviewed within 1 distinct art unit, which indicates a highly focused technical scope for the company's current patent efforts. The involvement of 1 distinct examiner suggests that the company's prosecution experience is centralized under a single official. This concentration in Biotechnology & Pharmaceuticals may allow for a more streamlined communication process, as there is only 1 pending office action to manage.
The busiest examiner for this portfolio is JUEDES, AMY E, who is responsible for 1 pending office action. As the company has only 1 pending office action in total, the decisions made by JUEDES, AMY E will have a significant impact on the current portfolio. The alignment of 1 distinct examiner with 1 distinct art unit ensures that the company can focus its legal strategy on the specific requirements of that unit. Practitioners should prioritize understanding the examination style of JUEDES, AMY E, as this individual manages the company's 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692600 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF IN THE MEDICAL FIELD | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692600 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF IN THE MEDICAL FIELD | JUEDES, AMY E | 1644 | §112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakis S R L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amy E Juedes has the most, with 1 of Takis S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
